Therapeutic Potential of Axl Blockade in BCR-ABL Negative Myeloproliferative Neoplasms (MPN)

被引：0
|
作者：
Beitzen-Heineke, Antonia [1 ,2 ,3 ]
Ben Batalla, Isabel [1 ,2 ,3 ]
Berenbrok, Nikolaus [1 ,2 ,3 ]
Paesler, Sarina [1 ,2 ,3 ]
Gensch, Victoria [1 ,2 ,3 ]
von Amsberg, Gunhild [1 ,2 ]
Schafhausen, Philippe [1 ,2 ]
Riecken, Kristoffer [4 ]
Fischer, Thomas [5 ]
Pantel, Klaus [3 ]
Bokemeyer, Carsten [1 ,2 ]
Loges, Sonja [1 ,2 ,3 ]
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Univ Comprehens Canc Ctr Hamburg, Hubertus Wald Tumorzentrum, Dept Hematol & Oncol,Sect BMT, Hamburg, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Univ Comprehens Canc Ctr Hamburg, Hubertus Wald Tumorzentrum, Dept Hematol & Oncol,Sect Pneumol, Hamburg, Germany
[3] Univ Med Ctr Hamburg Eppendorf, Ctr Med Expt, Inst Tumor Biol, Hamburg, Germany
[4] Univ Med Ctr Hamburg Eppendorf, Res Dept Cell & Gene Therapy, Dept Stem Cell Transplantat, Hamburg, Germany
[5] Otto Von Guericke Univ, Dept Hematol & Oncol, Magdeburg, Germany
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-118175
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3063
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort
    Elizabeth M. Kander
    Sania Raza
    Zheng Zhou
    Juehua Gao
    Anaadriana Zakarija
    Brandon J. McMahon
    Brady L. Stein
    International Journal of Hematology, 2015, 102 : 587 - 593
  • [42] Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort
    Kander, Elizabeth M.
    Raza, Sania
    Zhou, Zheng
    Gao, Juehua
    Zakarija, Anaadriana
    McMahon, Brandon J.
    Stein, Brady L.
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 102 (05) : 587 - 593
  • [43] Bcr: a negative regulator of the Bcr-Abl oncoprotein
    Wu, Y
    Ma, GZ
    Lu, D
    Lin, F
    Xu, HJ
    Liu, JX
    Arlinghaus, RB
    ONCOGENE, 1999, 18 (31) : 4416 - 4424
  • [44] Bcr: a negative regulator of the Bcr-Abl oncoprotein
    Yun Wu
    Guozhen Ma
    Dai Lu
    Feng Lin
    Hong-Ji Xu
    Jiaxin Liu
    Ralph B Arlinghaus
    Oncogene, 1999, 18 : 4416 - 4424
  • [45] Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders
    Mesa, Ruben A.
    BIOLOGICS-TARGETS & THERAPY, 2007, 1 (02): : 129 - 138
  • [46] Infections and vaccination in patients with BCR::ABL1 negative myeloproliferative neoplasms
    Haberbosch, S. M.
    Mertin, F.
    Hochhaus, A.
    Heidel, F.
    Hilgendorf, I
    Crodel, C. C.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 108 - 108
  • [47] Recombinant Interferon Alfa in BCR/ ABL-Negative Chronic Myeloproliferative Neoplasms
    El Bitar, Sandy
    Arcasoy, Murat O.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (02) : 80 - 89
  • [48] Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India
    Rabade, Nikhil
    Subramanian, P. G.
    Kodgule, Rohan
    Raval, Goutham
    Joshi, Swapnali
    Chaudhary, Shruti
    Mascarenhas, Russel
    Tembhare, Prashant
    Gujral, Sumeet
    Patkar, Nikhil
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2018, 61 (02) : 209 - 213
  • [49] Clinical Study of Lymphocyte Subsets in Patients with BCR/ABL Negative Myeloproliferative Neoplasms
    Li, Fei
    Chen, Ziwei
    Wang, Shixuan
    Yang, Renchi
    BLOOD, 2023, 142
  • [50] Pathogenesis of cardiovascular events in BCR-ABL1-negative myeloproliferative neoplasms
    Guy, Alexandre
    Poisson, Johanne
    James, Chloe
    LEUKEMIA, 2021, 35 (04) : 935 - 955
12345